Suppr超能文献

佐林格-埃利森综合征。胃酸分泌过多的识别与管理。

Zollinger-Ellison syndrome. Recognition and management of acid hypersecretion.

作者信息

Maton P N

机构信息

Oklahoma Foundation for Digestive Research, Oklahoma City, USA.

出版信息

Drugs. 1996 Jul;52(1):33-44. doi: 10.2165/00003495-199652010-00003.

Abstract

Zollinger-Ellison syndrome (ZES) should be suspected if a patient has severe peptic ulceration, ulcers and kidney stones, a family history of ulcers or endocrine diseases, watery diarrhoea or malabsorption with or without ulcers, or if hypergastrinaemia is found. Any patient in whom ZES is suspected, and certainly if diagnosed, should be given large doses of antisecretory medication immediately. This should never be stopped except under controlled conditions or unless acid outputs have been reduced surgically. Patients cannot be managed safely without measuring acid outputs. These should be lowered to < 10 mmol/h, or < 5 mmol/h in patients with a previous gastric resection or severe oesophageal disease. Acid secretion can be controlled acutely in 70% of patients with an infusion of ranitidine 1 mg/kg/h, while 4 mg/kg/h will control acid in all. The initial oral dosage of omeprazole or lansoprazole should be 60 mg/day. Doses should then be adjusted daily on the basis of acid outputs. Proton pump inhibitors in a dosage of 60 mg/day will control acid output in most patients and 60 mg every 12 hours will control acid output in all. Doses can then often be slowly and progressively reduced. A parietal cell vagotomy reduces acid secretion and reduces, but does not abolish, the need for antisecretory medication. In patients with multiple endocrine neoplasia type 1 and hyperparathyroidism, a parathyroidectomy that results in normocalcaemia will reduce acid secretion and drug requirements. A total gastrectomy is rarely if ever needed nowadays. Given the high degree of safety of gastric antisecretory medications versus the risks of acid hypersecretion in patients with ZES, the mistakes in management of acid hypersecretion that must be avoided are those of giving insufficient medication and not measuring acid secretory rates.

摘要

如果患者出现严重消化性溃疡、溃疡合并肾结石、有溃疡或内分泌疾病家族史、伴有或不伴有溃疡的水样腹泻或吸收不良,或者发现高胃泌素血症,则应怀疑患有佐林格-埃利森综合征(ZES)。任何疑似ZES的患者,确诊后当然应立即给予大剂量抗分泌药物。除非在可控条件下,或者酸分泌量已通过手术降低,否则绝不应停药。不测量酸分泌量就无法安全地治疗患者。应将酸分泌量降至<10 mmol/h,对于既往有胃切除术或严重食管疾病的患者,应降至<5 mmol/h。70%的患者静脉输注雷尼替丁1 mg/kg/h可急性控制酸分泌,而4 mg/kg/h可控制所有患者的酸分泌。奥美拉唑或兰索拉唑的初始口服剂量应为60 mg/天。然后应根据酸分泌量每日调整剂量。大多数患者每日服用60 mg的质子泵抑制剂可控制酸分泌量,每12小时服用60 mg可控制所有患者的酸分泌量。然后剂量通常可缓慢逐渐减少。壁细胞迷走神经切断术可减少酸分泌,并减少但不能消除对抗分泌药物的需求。对于患有1型多发性内分泌腺瘤病和甲状旁腺功能亢进的患者,甲状旁腺切除术后血钙正常可减少酸分泌和药物需求。如今很少需要进行全胃切除术。鉴于胃抗分泌药物的高度安全性与ZES患者酸分泌过多的风险相比,必须避免的酸分泌过多管理错误是药物使用不足和不测量酸分泌率。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验